Matching companies load automatically. Browse 24 companies per page; expand filters to narrow the results.
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
67 matching companiesShowing 49–67 / 67
Jenthera discloses an in vivo autologous CAR-T reprogramming program in B-cell lymphoma using targeted ribonucleoprotein genome editing and homology-directed insertion. Website tumor-eradication statements do not establish human efficacy.
ModeX, an OPKO company, lists MDX3001 as in vivo CAR-T for cancer and autoimmunity. Its platform conjugates CD3×CD28 antibodies to LNPs carrying CAR mRNA. Human dosing and the program’s precise current stage were not established by the accessible pipeline text.
Thesian’s ARIANE platform uses in vivo engineering to generate CAR-T and CAR-macrophages for oncology and autoimmune disease. The company describes lentiviral engineering expertise and a dual-lineage approach. A named clinical-stage candidate and patient efficacy were not verified.
GigaMune develops diverse viral pseudotypes for repeat-dose in vivo CAR-T delivery and shows anti-CD19 mouse proof of concept. Proposed sequential dosing and immune evasion are platform hypotheses; human redosing safety and efficacy have not been established.
YolTech explicitly lists YOLT-401 for autoimmune disease as an in vivo CAR-T program with an undisclosed target. Its clinical gene-editing programs are separate; their stages and delivery details are not automatically assigned to YOLT-401.
Immugenia discloses lentiviral in vivo CAR delivery to T/NK cells and HSCs, with promoter-restricted expression in T/NK lineages. HSC-derived replenishment differs from direct mature-T-cell engineering. The public disclosure does not establish a current CAR-T clinical phase.
An October 2026 company announcement describes an in vitro feasibility study combining FLT3 CAR mRNA with Nitto’s cell-targeted LNPs. This is an early in vivo CAR-T development effort, not human in vivo treatment. Clinical HG-CT-1 is a separate ex vivo product.
Nona supplies antibody discovery and CAR screening for Umoja’s in vivo CAR-T collaboration. The November 2025 agreement assigns subsequent product development and commercialization to Umoja. Nona is labeled an enabling partner, not a separately confirmed clinical CAR-T developer.
uBriGene provides lentiviral process development, GMP manufacturing, and regulatory support for Cellinfinity’s in vivo CAR-T programs. Its manufacturing partnership establishes an enabling role; it does not establish ownership of the therapeutic candidates.
Axelyf identifies AX-004 as its proprietary in vivo CAR-T candidate for solid tumors using AXL LNP delivery. Disclosed support is from mouse and non-human-primate studies; human dosing or clinical efficacy is not inferred.
Founded in 2023 and headquartered in Lexington, Mote was created by Fapon Group and Alex Wesselhoeft. Its mobilize platform enables targeted LNP/circRNA delivery. Its BIO 2026 presentation identifies a preclinical CD19/BCMA in vivo CAR-T lead; a projected November IIT is not proof of dosing.
Mana.bio applies machine learning to LNP design and disclosed a 2026 ASGCT presentation on progress toward in vivo CAR-T. The accessible material supports delivery-platform research; a named therapeutic candidate, clinical initiation, and patient efficacy were not verified.
The ESO-T01 Phase 1 publication includes a Pregene-affiliated coauthor alongside EsoBiotec. This establishes participation in the published work, not independent ownership of ESO-T01 or a separate verified in vivo CAR-T pipeline. Commercial rights require further confirmation.
Velvet discloses amino-acid nanoparticles and minicircle DNA for in vivo CAR delivery to multiple immune-cell types. The accessible primary page does not specify a T-cell program or clinical stage; it is retained as an adjacent CAR platform rather than counted as a confirmed CAR-T developer.
Singular’s iCAR is a recombinant fusion-protein approach to modifying T or NK cells in vivo. It is kept separate from gene-encoded CAR-T because protein-based receptor installation has a different mechanism. The website does not establish human efficacy.
ImmunoVec develops programmable DNA with cell-type-specific transcriptional control; the accessible primary disclosure highlights NK cells. It is tracked as adjacent in vivo immune engineering, without assuming that CAR-NK results establish a CAR-T program or clinical stage.
Liberate’s RAPTOR delivery platform supports initial in vivo CAR-macrophage programs through monocyte/macrophage reprogramming. CAR-M is a neighboring modality, not CAR-T; these programs are not included in the confirmed CAR-T developer count.
ImmTune discloses delivery vectors for in-body cell and gene therapy. Its accessible updates are old and do not establish a current named CAR-T program or clinical status. It remains a platform watchlist entry, outside the confirmed CAR-T developer count.
Sanofi acquired Tidal in April 2021 for its nanoparticle mRNA platform for in vivo immune-cell reprogramming, including CAR-T applications. This is a historical acquired-platform record; the original preclinical description is not a verified current program stage or an independent active biotech.
Coverage expands from sourced records; this database does not claim all biopharma companies.
